Department of Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Cancer Treat Rev. 2012 Aug;38(5):387-96. doi: 10.1016/j.ctrv.2011.08.001. Epub 2011 Aug 27.
The treatment of metastatic breast cancer (MBC) is essentially palliative and should be based on hormone therapy or optimized chemotherapy designed to delay disease progression and maximize survival with good quality of life. Novel chemotherapeutic agents introduced in the 1990 s include the taxanes (notably docetaxel), which are among the most potent of current anticancer drugs. Current research is also focusing on molecular targeted agents including those against the HER family of transmembrane receptors and vascular endothelial growth factor. Optimal effects are obtained when these compounds are used in combination with chemotherapy, as shown in preclinical models and more recently in clinical trials. Results of a large randomized trial have demonstrated a significant survival advantage for trastuzumab plus docetaxel compared with docetaxel monotherapy. Docetaxel plus bevacizumab combinations have recently been shown to significantly improve progression-free survival and objective response rate compared with docetaxel monotherapy. Overall, docetaxel in combination with novel targeted agents in MBC appears to be highly active in patients with MBC, and such combinations represent promising treatment regimens for clinical investigation.
转移性乳腺癌（MBC）的治疗主要是姑息性的，应基于激素治疗或优化化疗，旨在延缓疾病进展，延长生存时间并保持良好的生活质量。20 世纪 90 年代引入的新型化疗药物包括紫杉烷（特别是多西他赛），它们是目前最有效的抗癌药物之一。目前的研究还集中在分子靶向药物上，包括针对 HER 家族跨膜受体和血管内皮生长因子的药物。正如临床前模型和最近的临床试验所表明的那样，当这些化合物与化疗联合使用时，可获得最佳效果。一项大型随机试验的结果表明，与多西他赛单药治疗相比，曲妥珠单抗联合多西他赛治疗具有显著的生存优势。最近的研究表明，与多西他赛单药治疗相比，多西他赛联合贝伐珠单抗治疗可显著提高无进展生存期和客观缓解率。总的来说，多西他赛联合新型靶向药物治疗 MBC 在 MBC 患者中似乎具有很高的活性，这些联合治疗方案代表了有前途的治疗方案，值得进一步临床研究。
